000100.KS
000100.KS
KR7000100008
Yuhan
Loading chart...

Company Profile

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

Related stocks

128940.KS
128940.KS • South Korea
HanmiPharm
480,500 KRW
4.55B USD 1Y +35.5%
600329.SS
600329.SS • China
TIANJIN PHARMACEUTICAL DA REN T
35.8 CNY
4.13B USD 1Y -17.6%
002603.SZ
002603.SZ • China
YILING
15.53 CNY
3.88B USD 1Y -4.1%
RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%
4506.T
4506.T • Japan
SUMITOMO PHARMA CO LTD
1,591.5 JPY
4.51B USD 1Y -15.7%
000661.SZ
000661.SZ • China
CCHN
71.9 CNY
4.39B USD 1Y -44.4%
600079.SS
600079.SS • China
HUMANWELL HEALTHCARE (GROUP) CO
19.23 CNY
4.7B USD 1Y -10.1%
000739.SZ
000739.SZ • China
APELOA PHARMA.
25.4 CNY
4.4B USD 1Y +55.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
39.9% p.a.
Max Drawdown (5Y)
-59.4%
Sharpe Ratio (5Y)
0.12
Beta Factor
0.43
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (46.9%) is noticeably higher than the 5Y average (39.9%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -59.4% in the extended horizon.
ende